Small Cell Lung Cancer

These data are described in (Ying et al., 1995) and originally collected in (Maksymuik et al., 1994). The patients were randomly assigned to one of two treatments referred to as Arm A and Arm B. Arm A patients received cisplatin (P) followed by etoposide (E), while Arm B patients received (E) followed by (P). There were a total of 62 patients in Arm A with 15 right censored survival times, while Arm B consisted of 59 patients with 8 right censored survival times.<br><br>The variables recorded in the dataset(s) are:<br>- age: age of the patient upon entry (in years)<br>- time: survival time of the patient (in days)<br>- cens: indicator for survival time - 0 if observed, 1 if right censored<br><br>We analyze these data using a Dirichlet Process Mixture Model with a Gamma kernel distribution (Poynor and Kottas, 2017). The primary emphasis of our work is to obtain inference for the mean residual life function. Our code is shared through github (see link in references). <br><br>Journal References:<br><i><br></i><i>Jett, R, J D Earle, J Q Su, F A Diegert, J A Mailliard, C G Kardinal, J E Krook, M H Veeder, and M Wiesenfeld. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial</i>. A W Maksymiuk, J Journal of Clinical Oncology 1994 12:1, 70-76<br><br>Poynor V. and Kottas A. (2017). <i>Nonparametric Bayesian Inference for Mean Residual Life Functions in Survival Analysis</i>. Submitted to Biostatistics. arXiv:1411.7481 [stat.ME]. <br><br><i>Ying, Z., S. H. Jung and L. J. Wei. Survival Analysis with Median Regression Models. </i>Journal of the American Statistical Association, Vol. 90, No. 429 (Mar., 1995), pp.178-184<br> <br><br>